Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Barclays PLC

Barclays PLC lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 18.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 75,395 shares of the company’s stock after purchasing an additional 11,748 shares during the quarter. Barclays PLC owned 0.11% of Zentalis Pharmaceuticals worth $277,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ZNTL. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares during the period. Carson Advisory Inc. raised its position in shares of Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after buying an additional 8,800 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Finally, 49 Wealth Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 81.7% in the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock valued at $83,000 after acquiring an additional 10,145 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Stock Down 6.3 %

ZNTL opened at $2.24 on Tuesday. The firm has a market cap of $159.62 million, a PE ratio of -0.90 and a beta of 1.86. The business has a fifty day simple moving average of $3.17 and a 200-day simple moving average of $3.38. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.